The sequential decline from 12.8% in 2025Q2 to 12.3% in 2026Q2, despite record operating margin of 9.8%, suggests that while the company is capturing value from JDM initiatives, the pace of gross margin expansion may be moderating. Operating leverage is evident as operating margin expanded from 5.6% in 2024Q2 to 9.8% in 2026Q2, driven by SG&A efficiency, but the sustainability of this depends on continued CCS growth. Investors should monitor whether the 8.2% adjusted operating margin cited in recent guidance represents a ceiling, given the EPS miss versus consensus despite the beat-and-raise narrative.

The improvement in ROIC is driven by both margin expansion and asset turnover, with asset turnover rising from 0.38 in 2024Q1 to 0.52 in 2026Q2, reflecting better utilization of the expanded asset base. However, the 2025Q3 ROIC of 6.4% versus 8.8% in 2025Q2 suggests that returns are sensitive to working capital swings and capacity ramp costs. The recent capex surge to 5.6% of revenue may pressure near-term ROIC, but if the AI infrastructure demand persists, the investment could drive further compounding. The trend from 4.3% in 2024Q1 to 13.1% in 2026Q2 indicates a potential inflection point, but investors should verify that this is not a peak driven by temporary demand.

The CCC compression is notable, with DIO falling from 93 days to 67 days and DPO rising from 62 to 76 days over the same period, indicating that Celestica is managing inventory more efficiently and leveraging supplier terms. However, the quick ratio of 0.68 in 2026Q2, down from 0.78 in 2024Q1, suggests that liquidity is increasingly dependent on inventory, which could be a risk if demand softens. The improvement in DSO from 74 to 63 days reflects better receivables collection, but the 2026Q1 DPO drop to 62 days shows volatility in supplier leverage. This efficiency gain is a positive signal, but the reliance on inventory and the potential for customer concentration to disrupt payment terms warrant monitoring.

The balance sheet appears conservative with D/E of 0.33 and D/EBITDA of 1.75, down from 5.16 in 2024Q1, indicating reduced leverage relative to earnings. However, the 7x increase in capex to $263.8M in 2026Q2 suggests that the company may need to increase debt to fund capacity ahead of demand, which could raise leverage from its current low base. Interest coverage of 21.8x is robust, but the 2025Q1 coverage of 9.3x shows that it can compress quickly if EBITDA dips. The low D/E is a strength, but investors should monitor whether the company shifts toward higher debt utilization to finance growth, which could strain the balance sheet if the AI cycle turns.

The current ratio decline is driven by a 43% sequential jump in PPE, which is not a current asset, and a rise in current liabilities to fund working capital. The quick ratio of 0.68 suggests that the company relies heavily on inventory to meet short-term obligations, which could be problematic if inventory becomes obsolete or demand slows. Cash rose to $535.7M, but the cash conversion cycle improvement to 54 days may not fully offset the liquidity strain from rapid expansion. Under a severe stress scenario, such as a sudden drop in hyperscaler orders, the thin quick ratio could force the company to draw on credit lines or delay payables, though the low leverage provides a cushion.